Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
出版年份 2019 全文链接
标题
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-06-18
DOI
10.1093/annonc/mdz196
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
- (2019) Ping Qiu et al. Scientific Reports
- PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
- (2019) Yang Wang et al. Scientific Reports
- Liquid biopsy and minimal residual disease — latest advances and implications for cure
- (2019) Klaus Pantel et al. Nature Reviews Clinical Oncology
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
- (2019) B T Li et al. ANNALS OF ONCOLOGY
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
- (2019) Dominic G. Rothwell et al. NATURE MEDICINE
- The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
- (2019) Yaxiong Zhang et al. Journal for ImmunoTherapy of Cancer
- Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
- (2018) Yusuke Okuma et al. Clinical Lung Cancer
- Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
- (2018) Edward Kim et al. Clinical Lung Cancer
- Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma
- (2018) Yiwei Liu et al. Clinical Lung Cancer
- Tumor-specific neoantigens drive T-cell clonotype convergence
- (2018) J.C. Machado et al. EUROPEAN JOURNAL OF CANCER
- Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
- (2018) Masahiro Takeuchi et al. IMMUNOLOGY LETTERS
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
- (2018) Silvia Vecchiarelli et al. Oncotarget
- Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
- (2018) Teresa Morán et al. Oncotarget
- Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
- (2018) Manjima Dhar et al. Scientific Reports
- The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
- (2018) Ludmila Danilova et al. Cancer Immunology Research
- Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
- (2018) Galatea Kallergi et al. Therapeutic Advances in Medical Oncology
- PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma
- (2018) A. Asgarova et al. OncoImmunology
- Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
- (2018) Chunyan Yue et al. OncoImmunology
- Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
- (2018) Ryan N. Ptashkin et al. JAMA Oncology
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- The Parsortix™ Cell Separation System-A versatile liquid biopsy platform
- (2018) M. Craig Miller et al. CYTOMETRY PART A
- ClearCell® FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells
- (2018) Yifang Lee et al. CYTOMETRY PART A
- Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.
- (2018) Maria Jure-Kunkel et al. JOURNAL OF CLINICAL ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
- (2018) Luc Cabel et al. Nature Reviews Clinical Oncology
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients
- (2018) Samaresh Sau et al. Journal of Thoracic Disease
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients
- (2018) Taylor J Jensen et al. MOLECULAR CANCER THERAPEUTICS
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
- (2018) Markus Mayrhofer et al. Genome Medicine
- Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
- (2018) Sabrina A. Hogan et al. Cancer Immunology Research
- Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study
- (2018) Dragana Jovanovic et al. Journal of Thoracic Disease
- PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
- (2017) Paul Hofman EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- The feasibility of using mutation detection in ctDNA to assess tumor dynamics
- (2017) Xin Yi et al. INTERNATIONAL JOURNAL OF CANCER
- Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C
- (2017) Satoshi Yamagiwa et al. International Journal of Medical Sciences
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis
- (2017) Y. Chen et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
- (2017) Dorothea Sonja Schott et al. Oncotarget
- Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients
- (2017) Rasoul Nasiri Kalmarzi et al. ALLERGOLOGY INTERNATIONAL
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
- (2017) Jeffrey S. Weber et al. Cancer Immunology Research
- MicroRNA-146a-5p Limits Elevated TGF-β Signal during Cell Senescence
- (2017) Seung-Ki Min et al. Molecular Therapy-Nucleic Acids
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
- (2017) Florence Koeppel et al. PLoS One
- Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
- (2016) Archana Anantharaman et al. BMC CANCER
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis
- (2016) Koichi Yanaba et al. JOURNAL OF DERMATOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- (2016) Alena Gros et al. NATURE MEDICINE
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
- (2016) Ludmila Danilova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis
- (2016) Kristian Aarslev et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion
- (2016) Xue Pan et al. Experimental and Therapeutic Medicine
- Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
- (2016) Hyerim Ha et al. Oncotarget
- Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
- (2016) Xinqi Wu et al. Cancer Immunology Research
- The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study
- (2016) Gerit Theil et al. PLoS One
- High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1
- (2016) Jennifer L. Schehr et al. PLoS One
- Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients
- (2016) Arun Satelli et al. Scientific Reports
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
- (2016) Chiara Nicolazzo et al. Scientific Reports
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- PD-L1 expression by circulating breast cancer cells
- (2015) Rachel David LANCET ONCOLOGY
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer
- (2015) Qiu-Xia Qu et al. TUMOR BIOLOGY
- Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
- (2015) Joao Paulo Oliveira-Costa et al. Oncotarget
- Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
- (2015) Elin S. Gray et al. Oncotarget
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch®CTC test
- (2014) Daniel L. Adams et al. CYTOMETRY PART A
- Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
- (2014) Evan J Lipson et al. Journal for ImmunoTherapy of Cancer
- Size-selective collection of circulating tumor cells using Vortex technology
- (2013) Elodie Sollier et al. LAB ON A CHIP
- Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases
- (2013) Bimin Shi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation